

Gamal Esmat

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1731711/publications.pdf>

Version: 2024-02-01

166
papers

4,438
citations

145106

33
h-index

150775

59
g-index

171
all docs

171
docs citations

171
times ranked

5835
citing authors

#	ARTICLE	IF	CITATIONS
1	Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status. American Journal of Therapeutics, 2024, 31, e72-e81.	0.5	0
2	Derivation of "Egyptian varices prediction (EVP) index": A novel noninvasive index for diagnosing esophageal varices in HCV Patients. Journal of Advanced Research, 2022, 35, 87-97.	4.4	1
3	HCV/HIV coinfecting Egyptian patients: a cross-sectional study of their main characteristics and barriers to HCV treatment initiation. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, 116, 227-232.	0.7	3
4	Real-life experience of treating HCV co-infection among HIV-infected population in Egypt: single-center experience. Expert Review of Anti-Infective Therapy, 2022, 20, 789-795.	2.0	2
5	HIV-related stigma and discrimination by healthcare workers in Egypt. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2022, , .	0.7	2
6	The Egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi Journal of Gastroenterology, 2022, 28, 3.	0.5	12
7	Determining the lower limit of detection required for HCV viral load assay for test of cure following direct-acting antiviral-based treatment regimens: Evidence from a global data set. Journal of Viral Hepatitis, 2022, 29, 474-486.	1.0	3
8	The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. Journal of Hepatology, 2022, 76, 771-780.	1.8	114
9	Egyptian revalidation of non-invasive parameters for predicting esophageal varices in cirrhotic patients: A retrospective study. Arab Journal of Gastroenterology, 2022, 23, 120-124.	0.4	1
10	The Impact of Direct-Acting Antiviral Agents on Cytomegalovirus Reactivation in Chronic Hepatitis C Infection. Asian Pacific Journal of Cancer Prevention, 2022, 23, 1365-1372.	0.5	0
11	Improvement of platelet in thrombocytopenic HCV patients after treatment with direct-acting antiviral agents and its relation to outcome. Platelets, 2021, 32, 383-390.	1.1	5
12	WGO Guidance for the Care of Patients With COVID-19 and Liver Disease. Journal of Clinical Gastroenterology, 2021, 55, 1-11.	1.1	37
13	The interrelation between lipid profile in chronic HCV patients and their response to antiviral agents. Expert Review of Gastroenterology and Hepatology, 2021, 15, 103-110.	1.4	3
14	OUP accepted manuscript. Journal of Public Health, 2021, , .	1.0	0
15	Anticancer activity of milk fat rich in conjugated linoleic acid against Ehrlich ascites carcinoma cells in female Swiss albino mice. Veterinary World, 2021, 14, 696-708.	0.7	6
16	Management of liver disease patients in different clinical situations during COVID-19 pandemic. Egyptian Liver Journal, 2021, 11, 21.	0.3	5
17	Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohort. Liver International, 2021, 41, 1494-1497.	1.9	15
18	Gastrointestinal manifestations of human immunodeficiency virus and coronavirus disease 2019: Understanding the intersecting regions between the two epidemics. Arab Journal of Gastroenterology, 2021, 22, 75-87.	0.4	2

#	ARTICLE	IF	CITATIONS
19	Micro-elimination of hepatitis C among people living with HIV in Egypt. <i>Liver International</i> , 2021, 41, 1445-1447.	1.9	2
20	Hepatitis C viral RNA in blood mononuclear cells of patients treated with directly acting antivirals. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 158-163.	0.4	0
21	Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study. <i>Journal of Medical Virology</i> , 2021, 93, 5833-5838.	2.5	79
22	Long-term clinical outcomes in sustained responders with chronic hepatitis C after treatment with direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	1
23	Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. <i>Expert Review of Anti-Infective Therapy</i> , 2021, , 1-8.	2.0	4
24	Hepatitis C elimination in Africa: Seizing the moment for hepatitis-C free future. <i>Arab Journal of Gastroenterology</i> , 2021, 22, 249-251.	0.4	2
25	Predictors of severity and development of critical illness of Egyptian COVID-19 patients: A multicenter study. <i>PLoS ONE</i> , 2021, 16, e0256203.	1.1	16
26	Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study. <i>International Immunopharmacology</i> , 2021, 99, 108004.	1.7	10
27	OUP accepted manuscript. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, , .	0.7	1
28	OUP accepted manuscript. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2021, , .	0.7	0
29	Eliminating hepatitis C from countries with high prevalence: When infrastructure comes first. <i>Indian Journal of Medical Research</i> , 2021, 154, 1.	0.4	2
30	Impact of Toll-like Receptors 2(TLR2) and TLR 4 Gene Variations on HCV Susceptibility, Response to Treatment and Development of Hepatocellular Carcinoma in Cirrhotic HCV Patients. <i>Immunological Investigations</i> , 2020, 49, 462-476.	1.0	30
31	Serum visfatin level as a noninvasive marker for nonalcoholic fatty liver disease in children and adolescents with obesity: relation to transient elastography with controlled attenuation parameter. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 1008-1016.	0.8	19
32	Securing sustainable funding for viral hepatitis elimination plans. <i>Liver International</i> , 2020, 40, 260-270.	1.9	24
33	Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. <i>Liver International</i> , 2020, 40, 797-805.	1.9	22
34	Renal profile of chronic hepatitis C patients with sofosbuvir-based therapy. <i>Infection</i> , 2020, 48, 913-922.	2.3	2
35	Assessment of facility performance during mass treatment of chronic hepatitis C in Egypt: Enablers and obstacles. <i>Journal of Infection and Public Health</i> , 2020, 13, 1322-1329.	1.9	9
36	HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection. <i>Environmental Science and Pollution Research</i> , 2020, 27, 33659-33667.	2.7	13

#	ARTICLE	IF	CITATIONS
37	Screening and Treatment Program to Eliminate Hepatitis C in Egypt. <i>New England Journal of Medicine</i> , 2020, 382, 1166-1174.	13.9	160
38	Emerging from the screening of 57 million citizens and treating 4 million patients: future strategies to eliminate hepatitis C from Egypt. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 637-642.	2.0	13
39	Sustained virologic response and changes in liver fibrosis parameters following 12-wk administration of generic sofosbuvir and daclatasvir in HIV/HCV-coinfected patients with HCV genotype 4 infection. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2020, 114, 232-240.	0.7	5
40	Antiretroviral therapy optimisation in the time of COVID-19: Is it really different in North and South Africa?. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1118.	0.3	3
41	COVID-19 crisis effect on HIV service delivery in Egypt: Hard times or blessings in disguise?. <i>Southern African Journal of HIV Medicine</i> , 2020, 21, 1170.	0.3	2
42	Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life Egyptian experience. <i>Journal of Medical Virology</i> , 2019, 91, 668-676.	2.5	4
43	Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2019, 91, 272-277.	2.5	20
44	Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1009-1016.	1.4	5
45	Egyptian recommendations for management of <i>Helicobacter pylori</i> infection: 2018 report. <i>Arab Journal of Gastroenterology</i> , 2019, 20, 175-179.	0.4	17
46	High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 907-914.	1.4	4
47	DAA's therapy associated with improved hepatic fibrosis in HCV-GT4 patients co-infected with HIV. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 693-698.	1.4	8
48	Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma: The debate continues – A mini-review. <i>Journal of Advanced Research</i> , 2019, 17, 43-48.	4.4	13
49	Epigallocatechin gallate (EGCG) and miR-548m reduce HCV entry through repression of CD81 receptor in HCV cell models. <i>Archives of Virology</i> , 2019, 164, 1587-1595.	0.9	27
50	Hepatitis C Virus in Egypt: Interim Report From the World's Largest National Program. <i>Clinical Liver Disease</i> , 2019, 14, 203-206.	1.0	16
51	Clinical impact of serum α -fetoprotein and its relation on changes in liver fibrosis in hepatitis C virus patients receiving direct-acting antivirals. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1129-1134.	0.8	13
52	Circulating microRNAs (miR-21, miR-223, miR-885-5p) along the clinical spectrum of HCV-related chronic liver disease in Egyptian patients. <i>Arab Journal of Gastroenterology</i> , 2019, 20, 198-204.	0.4	12
53	Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. <i>Gut</i> , 2019, 68, 721-728.	6.1	34
54	Diabetes Association with Liver Diseases: An Overview for Clinicians. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2019, 19, 274-280.	0.6	22

#	ARTICLE	IF	CITATIONS
55	Comparing the efficiency of Fib4, Forns score, APRI, and GUCI in liver fibrosis staging in Egyptians with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2018, 90, 1106-1111.	2.5	13
56	HCV in Egypt, prevention, treatment and key barriers to elimination. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 345-350.	2.0	43
57	Spur-of-the-Moment Modification in National Treatment Policies Leads to a Surprising HCV Viral Suppression in All Treated Patients: Real-Life Egyptian Experience. <i>Journal of Interferon and Cytokine Research</i> , 2018, 38, 81-85.	0.5	5
58	Novel scores combining AFP with noninvasive markers for prediction of liver fibrosis in chronic hepatitis C patients. <i>Journal of Medical Virology</i> , 2018, 90, 1080-1086.	2.5	18
59	After successful hepatitis C virus antiviral therapy: It looks that normal alanine aminotransferase level is not the normal. <i>Journal of Clinical Laboratory Analysis</i> , 2018, 32, .	0.9	4
60	Effectiveness of sofosbuvir plus ledipasvir in interferon-naïve and treated patients with chronic hepatitis C genotype-4. <i>Journal of Hepatology</i> , 2018, 68, 53-62.	1.8	17
61	Planning and prioritizing direct-acting antivirals treatment for HCV patients in countries with limited resources: Lessons from the Egyptian experience. <i>Journal of Hepatology</i> , 2018, 68, 691-698.	1.8	50
62	Managing diabetes and liver disease association. <i>Arab Journal of Gastroenterology</i> , 2018, 19, 166-179.	0.4	27
63	One step closer to elimination of hepatitis C in Egypt. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 665.	3.7	26
64	High sustained virologic response rate using generic directly acting antivirals in the treatment of chronic hepatitis C virus Egyptian patients: single-center experience. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 1194-1199.	0.8	7
65	Real-Life Efficacy of 5 Different Antiviral Regimens for Treatment of Chronic Hepatitis C With Normal Liver Enzymes. <i>American Journal of Therapeutics</i> , 2018, 25, e776-e779.	0.5	1
66	An account of the real-life hepatitis C management in a single specialized viral hepatitis treatment centre in Egypt: results of treating 7042 patients with 7 different direct acting antiviral regimens. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 1265-1272.	1.4	20
67	A New Potent NS5A Inhibitor in the Management of Hepatitis C Virus: Ledipasvir. <i>Current Drug Discovery Technologies</i> , 2018, 15, 24-31.	0.6	6
68	Disruption of Claudin-1 Expression by miRNA-182 Alters the Susceptibility to Viral Infectivity in HCV Cell Models. <i>Frontiers in Genetics</i> , 2018, 9, 93.	1.1	9
69	Evaluation of accuracy of elastography point quantification versus other noninvasive modalities in staging of fibrosis in chronic hepatitis C virus patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 882-887.	0.8	6
70	Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data. <i>Liver International</i> , 2018, 38, 2159-2169.	1.9	15
71	Methylation in MIRLET7A3 Gene Induces the Expression of IGF-II and Its mRNA Binding Proteins IGF2BP-2 and 3 in Hepatocellular Carcinoma. <i>Frontiers in Physiology</i> , 2018, 9, 1918.	1.3	12
72	Role of relevant immune-modulators and cytokines in hepatocellular carcinoma and premalignant hepatic lesions. <i>World Journal of Gastroenterology</i> , 2018, 24, 1228-1238.	1.4	19

#	ARTICLE	IF	CITATIONS
73	Parasitic Liver Disease. , 2018, , 568-578.e4.		0
74	Changes in liver stiffness measurements and fibrosis scores following sofosbuvir based treatment regimens without interferon. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1624-1630.	1.4	71
75	Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients. Expert Review of Gastroenterology and Hepatology, 2017, 11, 773-778.	1.4	27
76	Response to Real life Egyptian experience of Efficacy / safety of Simeprevir Sofosbuvir in <scp>HCV</scp> genotype IV</scp>. Liver International, 2017, 37, 766-766.	1.9	1
77	Discovery and preclinical development of dasabuvir for the treatment of hepatitis C infection. Expert Opinion on Drug Discovery, 2017, 12, 635-642.	2.5	13
78	Herpes Zoster reactivation in patients with chronic hepatitis C under treatment with directly acting antiviral agents: A case series. Arab Journal of Gastroenterology, 2017, 18, 39-41.	0.4	10
79	Impact of old Schistosomiasis infection on the use of transient elastography (Fibroscan) for staging of fibrosis in chronic HCV patients. Acta Tropica, 2017, 176, 283-287.	0.9	6
80	Improvement of glycemic state among responders to Sofosbuvir based treatment regimens: Single center experience. Journal of Medical Virology, 2017, 89, 2181-2187.	2.5	39
81	Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Journal of Interferon and Cytokine Research, 2017, 37, 348-353.	0.5	4
82	Establishing ultrasound based transient elastography cutoffs for different stages of hepatic fibrosis and cirrhosis in Egyptian chronic hepatitis C patients. Arab Journal of Gastroenterology, 2017, 18, 210-215.	0.4	3
83	Ectopic delivery of miR-200c diminishes hepatitis C virus infectivity through transcriptional and translational repression of Occludin. Archives of Virology, 2017, 162, 3283-3291.	0.9	9
84	miR-148a and miR-30a limit HCV dependent suppression of the lipid droplet protein, ADRP, in HCV infected cell models. Journal of Medical Virology, 2017, 89, 653-659.	2.5	7
85	Extrahepatic manifestations in hepatitis C virus infection. Journal of Advanced Research, 2017, 8, 85-87.	4.4	8
86	Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic <scp>HCV</scp> genotype IV</scp> infected patients. Liver International, 2017, 37, 534-541.	1.9	51
87	Study of the Humoral Immune Response towards HCV Genotype 4 Using a Bead-Based Multiplex Serological Assay. High-Throughput, 2017, 6, 15.	4.4	2
88	IL-17 Induced The Recruitment and Functional Activity of Granulocytes Isolated from Patients Coinfected with Schistosoma mansoni and Hepatitis C Virus. The Egyptian Journal of Immunology / Egyptian Association of Immunologists, 2017, 24, 9-20.	0.1	0
89	Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surgery and Nutrition, 2016, 5, 209-216.	0.7	14
90	Losartan may inhibit the progression of liver fibrosis in chronic HCV patients. Hepatobiliary Surgery and Nutrition, 2016, 5, 249-255.	0.7	24

#	ARTICLE	IF	CITATIONS
91	Accurate Prediction of Advanced Liver Fibrosis Using the Decision Tree Learning Algorithm in Chronic Hepatitis C Egyptian Patients. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-7.	0.7	26
92	Seroprevalence of HCV among Cairo University students in Egypt. <i>Journal of Medical Virology</i> , 2016, 88, 1384-1387.	2.5	6
93	FibroScan, APRI, FIB4, and GUCI: Role in prediction of fibrosis and response to therapy in Egyptian patients with HCV infection. <i>Arab Journal of Gastroenterology</i> , 2016, 17, 78-83.	0.4	25
94	Management of Hepatitis C Virus Genotypes 4, 5, and 6 Using Direct Antiviral Agents: Review of Current Status. <i>Current Treatment Options in Infectious Diseases</i> , 2016, 8, 368-378.	0.8	0
95	Diagnostic accuracy of the Γ^3 -glutamyl transpeptidase to platelet ratio to predict liver fibrosis in Egyptian patients with HCV genotype 4. <i>Gut</i> , 2016, 65, 1577-1578.	6.1	5
96	Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 1413-1421.	1.3	13
97	Safety of direct antiviral agents in the management of hepatitis C. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1643-1652.	1.0	36
98	Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large, International Cohort Studies. <i>Advances in Therapy</i> , 2016, 33, 1797-1813.	1.3	2
99	Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 36-44.	3.7	61
100	Abrogating the interplay between IGF2BP1, 2 and 3 and IGF1R by let-7i arrests hepatocellular carcinoma growth. <i>Growth Factors</i> , 2016, 34, 42-50.	0.5	36
101	MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc. <i>Oncology Letters</i> , 2016, 12, 2567-2573.	0.8	66
102	Enhancing NK cell cytotoxicity by miR-182 in hepatocellular carcinoma. <i>Human Immunology</i> , 2016, 77, 667-673.	1.2	44
103	Predictors of Virological Response in 3,235 Chronic HCV Egyptian Patients Treated with Peginterferon Alpha-2a Compared with Peginterferon Alpha-2b Using Statistical Methods and Data Mining Techniques. <i>Journal of Interferon and Cytokine Research</i> , 2016, 36, 338-346.	0.5	7
104	Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt. <i>Journal of Hepatology</i> , 2016, 64, 1240-1246.	1.8	15
105	Contradicting roles of miR-182 in both NK cells and their host target hepatocytes in HCV. <i>Immunology Letters</i> , 2016, 169, 52-60.	1.1	15
106	miR-34a: Multiple Opposing Targets and One Destiny in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 300-305.	0.7	5
107	HCV Infection Amplified Th2 Bias and Th17 Responses In Schistosoma-Infected Patients. <i>The Egyptian Journal of Immunology / Egyptian Association of Immunologists</i> , 2016, 23, 87-96.	0.1	0
108	A pleiotropic effect of the single clustered hepatic metastamiRs miR-96-5p and miR-182-5p on insulin-like growth factor II, insulin-like growth factor-1 receptor and insulin-like growth factor-binding protein-3 in hepatocellular carcinoma. <i>Molecular Medicine Reports</i> , 2015, 12, 645-650.	1.1	22

#	ARTICLE	IF	CITATIONS
109	Epsteinâ€Barr virus and Interleukin-28B polymorphism in the prediction of response to interferon therapy in hepatitis C patients. Arab Journal of Gastroenterology, 2015, 16, 84-89.	0.4	1
110	Transcriptional activation of the IGF-II/IGF-1R axis and inhibition of IGFBP-3 by miR-155 in hepatocellular carcinoma. Oncology Letters, 2015, 10, 3206-3212.	0.8	20
111	Expression signature of microRNA-155 in hepatitis C virus genotype 4 infection. Biomedical Reports, 2015, 3, 93-97.	0.9	19
112	miRâ€1275: A single microRNA that targets the three IGF2â€mRNAâ€binding proteins hindering tumor growth in hepatocellular carcinoma. FEBS Letters, 2015, 589, 2257-2265.	1.3	57
113	Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4. Arab Journal of Gastroenterology, 2015, 16, 50-53.	0.4	31
114	How to optimize hepatitis C virus treatment impact on life years saved in resourceâ€constrained countries. Hepatology, 2015, 62, 31-39.	3.6	25
115	Repressing PU.1 by miR-29aâ€ in NK cells of HCV patients, diminishes its cytolytic effect on HCV infected cell models. Human Immunology, 2015, 76, 687-694.	1.2	8
116	Epigenetic harnessing of HCV via modulating the lipid dropletâ€protein, TIP47, in HCV cell models. FEBS Letters, 2015, 589, 2266-2273.	1.3	5
117	New era for management of chronic hepatitis C virus using direct antiviral agents: A review. Journal of Advanced Research, 2015, 6, 301-310.	4.4	40
118	Mir-194 is a hepatocyte gate keeper hindering HCV entry through targeting CD81 receptor. Journal of Infection, 2015, 70, 78-87.	1.7	20
119	Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin. Journal of Interferon and Cytokine Research, 2015, 35, 49-54.	0.5	37
120	Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut, 2015, 64, 948-956.	6.1	101
121	Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients. Biomedical Reports, 2014, 2, 843-848.	0.9	12
122	Optimizing treatment for <sc>HCV</sc> genotype 4: PEGâ€IFN alfa 2a vs. PEGâ€IFN alfa 2b; the debate continues. Liver International, 2014, 34, 24-28.	1.9	28
123	Tamoxifen downregulates MxA expression by suppressing TLR7 expression in PBMCs of males infected with HCV. Journal of Medical Virology, 2014, 86, 1113-1119.	2.5	2
124	Is expert opinion reliable when estimating transition probabilities? The case of HCV-related cirrhosis in Egypt. BMC Medical Research Methodology, 2014, 14, 39.	1.4	2
125	Effect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. The Lancet Global Health, 2014, 2, e541-e549.	2.9	42
126	Effectiveness and Cost-effectiveness of Immediate Versus Delayed Treatment of Hepatitis C Virusâ€Infected Patients in a Country With Limited Resources: The Case of Egypt. Clinical Infectious Diseases, 2014, 58, 1064-1071.	2.9	34

#	ARTICLE	IF	CITATIONS
127	The current and future disease burden of chronic hepatitis C virus infection in Egypt. Arab Journal of Gastroenterology, 2014, 15, 45-52.	0.4	88
128	Liver Biopsy and FibroScan to Detect Early Histopathological Changes in Chronic HBV Patients Not Candidate for Treatment. Gastroenterology Research, 2014, 7, 56-63.	0.4	1
129	Virologic response and breakthrough in chronic hepatitis B Egyptian patients receiving lamivudine therapy. Annals of Gastroenterology, 2014, 27, 380-386.	0.4	4
130	Hepatic and Intestinal Schistosomiasis: Review. Journal of Advanced Research, 2013, 4, 445-452.	4.4	161
131	Fibroscan of chronic HCV patients coinfecting with schistosomiasis. Arab Journal of Gastroenterology, 2013, 14, 109-112.	0.4	20
132	How to optimize HCV therapy in genotype 4 patients. Liver International, 2013, 33, 41-45.	1.9	14
133	Progesterone suppresses interferon signaling by repressing TLR-7 and MxA expression in peripheral blood mononuclear cells of patients infected with hepatitis C virus. Archives of Virology, 2013, 158, 1755-1764.	0.9	19
134	Human Schistosomiasis: Clinical Perspective: Review. Journal of Advanced Research, 2013, 4, 433-444.	4.4	141
135	Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	5
136	Hypertonic saline-enhanced radiofrequency versus chemoembolization sequential radiofrequency in the treatment of large hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 628-633.	0.8	9
137	Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children. Liver International, 2012, 32, 449-456.	1.9	22
138	Accurate Prediction of Response to Interferon-based Therapy in Egyptian Patients with Chronic Hepatitis C Using Machine-learning Approaches. , 2012, , .		8
139	Repressed induction of interferon-related microRNAs miR-146a and miR-155 in peripheral blood mononuclear cells infected with HCV genotype 4. FEBS Open Bio, 2012, 2, 179-186.	1.0	33
140	Estrogen-related MxA transcriptional variation in hepatitis C virus-infected patients. Translational Research, 2012, 159, 190-196.	2.2	12
141	NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferon-Ribavirin Therapy in Egyptian Patients. Journal of Clinical Microbiology, 2012, 50, 3886-3892.	1.8	17
142	Epidermal growth factor gene polymorphism 61A/G in patients with chronic liver disease for early detection of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	0.8	13
143	HLA Tissue Typing Has No Effect on the Outcome of Patients Undergoing a Living-donor Liver Transplant: A Single-center Experience in Egypt. Experimental and Clinical Transplantation, 2012, 10, 136-140.	0.2	0
144	Human cytomegalovirus infection inhibits response of chronic hepatitis C virus-infected patients to interferon-based therapy. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 55-62.	1.4	27

#	ARTICLE	IF	CITATIONS
145	Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 843-850.	1.4	42
146	A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. <i>Liver International</i> , 2011, 31, 61-80.	1.9	481
147	Strong Hepatitis C Virus (HCV) specific Cell-mediated Immune Responses in the Absence of Viremia or Antibodies Among Uninfected Siblings of HCV Chronically Infected Children. <i>Journal of Infectious Diseases</i> , 2011, 203, 854-861.	1.9	27
148	Disease progression from chronic hepatitis C to cirrhosis and hepatocellular carcinoma is associated with repression of interferon regulatory factor-1. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 450-456.	0.8	8
149	Prevalence of rheumatologic manifestations of chronic hepatitis C virus infection among Egyptians. <i>Clinical Rheumatology</i> , 2010, 29, 1373-1380.	1.0	47
150	Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4. <i>Comparative Hepatology</i> , 2010, 9, 1.	0.9	31
151	Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus. <i>Pediatric Diabetes</i> , 2010, 11, 462-470.	1.2	26
152	Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. <i>Gut</i> , 2010, 59, 1135-1140.	6.1	87
153	A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. <i>Phytomedicine</i> , 2009, 16, 391-400.	2.3	82
154	Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. <i>Journal of Medical Virology</i> , 2009, 81, 1576-1583.	2.5	47
155	Antischistosomal therapy: Current status and recent developments. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 1-3.	0.4	5
156	Quality of life of Egyptian donors after living-related liver transplantation. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 21-24.	0.4	5
157	Study of the enhancing effect of sodium chloride injection on radiofrequency ablation of hepatocellular carcinoma. <i>Arab Journal of Gastroenterology</i> , 2009, 10, 63-67.	0.4	4
158	Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. <i>Liver International</i> , 2008, 28, 1112-1119.	1.9	43
159	Genetic diversity in hepatitis C virus in Egypt and possible association with hepatocellular carcinoma. <i>Journal of General Virology</i> , 2007, 88, 1526-1531.	1.3	121
160	Changing Patterns of Acute Viral Hepatitis at a Major Urban Referral Center in Egypt. <i>Clinical Infectious Diseases</i> , 2007, 44, e30-e36.	2.9	51
161	Serum Î±-Foetoprotein Level Predicts Treatment Outcome in Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2007, 12, 797-803.	0.6	33
162	HCV-related morbidity in a rural community of Egypt. <i>Journal of Medical Virology</i> , 2006, 78, 1185-1189.	2.5	40

#	ARTICLE	IF	CITATIONS
163	Role of hepatitis C infection in chronic liver disease in Egypt.. American Journal of Tropical Medicine and Hygiene, 2002, 67, 436-442.	0.6	102
164	High Seroprevalence of Hepatitis C Infection among Risk Groups in Egypt. American Journal of Tropical Medicine and Hygiene, 1994, 51, 563-567.	0.6	120
165	Is Schistosoma mansoni Replacing Schistosoma haematobium in the Fayoum?. American Journal of Tropical Medicine and Hygiene, 1993, 49, 697-700.	0.6	24
166	Grading of Hepatic Schistosomiasis by the Use of Ultrasonography. American Journal of Tropical Medicine and Hygiene, 1992, 46, 403-408.	0.6	102